Floatz logo

Eptinezumab

Medication Overuse Headache

Beijing Tiantan Hospitalmonoclonal_antibodyPhase 4 / ApprovedActive
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Medication Overuse Headache cohort.

Asset / SponsorPhaseRating
Frovatriptan
University of Calgary
Phase 2B
IMMUNOGLOBULIN G, ANTI-(HUMAN CALCITONIN GENE-RELATED PEPTIDE RECEPTOR) (HUMAN MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LIGHT CHAIN, DIMER
Beijing Tiantan Hospital
D
Yangxue Qingnao Granules
Beijing Tiantan Hospital
D
Topamax
Ataturk University
N/AD
Treximet®
IRCCS San Raffaele Roma
D

View all 9 →

Same molecule, other indications

Eptinezumab is also rated in:

migraine disorderDormant
BBB
Indicative ·
79 / 100
View asset →
Migraine Associated VertigoDormant
B
Indicative ·
62 / 100
View asset →
tinnitusDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →